



Veracyte to Participate in Upcoming Investor Conferences

October 30, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 30, 2024-- [Veracyte, Inc.](https://www.veracyte.com) (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.

- **UBS Healthcare Conference – Rancho Palos Verdes, CA**
Fireside Chat on November 12th at 2:45 p.m. Eastern Time
- **Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA**
Fireside Chat on November 13th at 3:00 p.m. Eastern Time
- **Wolfe Research Healthcare Conference – New York, NY**
Fireside Chat on November 19th at 1:40 p.m. Eastern Time
- **Stephens Annual Investor Conference – Nashville, TN**
Fireside Chat on November 20th at 4:00 p.m. Eastern Time

Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at <http://investor.veracyte.com/events-presentations>. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on [LinkedIn](#) or [X \(Twitter\)](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241029391463/en/): <https://www.businesswire.com/news/home/20241029391463/en/>

Investors:

Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:

Tracy Morris
media@veracyte.com
(650) 380-4413

Source: Veracyte, Inc.